ClinicalTrials.gg
Enrolling by invitationNCT05889416Updated Nov 29, 2024

The Perfect-CR Implementation Study

An interventional study of Audit and feedback through a quality registry and Implementation support in Myocardial Infarction and Risk Reduction, sponsored by Skane University Hospital. Enrolling by invitation at 1 site in Sweden. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2024-11-29.

Sponsored by Skane University Hospital · Not applicable, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 90 studies in Myocardial Infarction with a site in Sweden — 13 open to participants now, 22 under way, 4 of them phase 3. Myocardial Infarction · Sweden.

Planned enrollment
60th of 70
75 · median 875
Started
2023
with 3 others
No phase
23 of 90
6 open now
Primary completion
2026-12
later than 9 of 21 live
Registered
77th of 90
by date

Among the 90 studies in Myocardial Infarction with a site in Sweden, this one is the 60th largest by planned enrollment of the 70 interventional ones that give a count, is one of 4 that started in 2023, is one of 23 with no phase, reaches primary completion later than 9 of the 21 other live ones, and was the 77th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

13 of the 90 studies in Myocardial Infarction with a site in Sweden are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in Myocardial Infarction with a site in Sweden, or all of them as a file.
02

Study summary

The goal of this open-label cluster-randomized effectiveness-implementation hybrid trial is to study whether a) audit and feedback of cardiac rehabilitation service delivery within a national quality registry and b) structured implementation support can improve center-level adherence to guidelines and short and long-term patient-level outcomes.

Read the detailed description

Administering secondary prevention via structured cardiac rehabilitation (CR) programs for patients who have suffered a myocardial infarction (MI) reduces mortality and morbidity and improves quality of life. Still, treatment goal achievement at patient-level and service delivery at center-level are sub-optimal and there is a large variation in program structure and delivery at center-level.

Using an open-label cluster-randomized effectiveness-implementation hybrid trial design, the primary objective of this study is to prospectively evaluate whether a) audit and feedback of CR processes and structures within the national cardiac registry SWEDEHEART and b) supporting CR centers in implementing CR guidelines can increase center-level guideline adherence. The secondary objectives are the following:

  • At baseline, to cross-sectionally evaluate the association between center-level adherence to guidelines and patient-level outcomes
  • To prospectively study whether audit and feedback of CR processes and structures within the SWEDEHEART registry can improve short- and long-term patient-level outcomes
  • To prospectively evaluate whether supporting CR centers in implementing CR guidelines can improve short- and long-term patient-level outcomes
  • To evaluate the acceptability, adoption, fidelity, implementation cost, and cost effectiveness of the implementation support

All CR centers in Sweden (approximately 75 centers) will be offered participation in the study. Collectively these centers attend to approximately 8000 patients/year. Patient-level outcome data will be retrieved from national registries.

03

Conditions studied

  • Myocardial Infarction
  • Risk Reduction

Keywords

  • Myocardial infarction
  • Cardiac rehabilitation
  • Secondary prevention
  • Audit
  • Implementation
  • Practice facilitation
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Centre-level

Inclusion Criteria:

  • Centres report to the SWEDEHEART registry

Exclusion Criteria:

  • Unwillingness to participate in the study

Patient-level

Inclusion Criteria:

  • Diagnosis of a type 1 MI registered in the SWEDEHEART registry
  • Age 18-79 years at discharge from hospital
  • Attended at least two follow-up visits at CR centres included in the study

Exclusion Criteria:

  • None
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • No intervention
    Usual care

    Implementation of national guidelines on secondary prevention according to local plan and preferences

  • Active comparator
    Audit and feedback

    Audit and feedback on implementation of national guidelines on secondary prevention through the national quality registry SWEDEHEART

    Other: Audit and feedback through a quality registry

  • Active comparator
    Implementation support

    Audit and feedback through the national quality registry SWEDEHEART and structured implementation support for implementation of national guidelines on secondary prevention

    Other: Audit and feedback through a quality registry · Other: Implementation support

Interventions

  • OtherAudit and feedback through a quality registry

    Centres answer CR process and structure variables through the SWEDEHEART registry every six months for three years. Feedback will be accessible online and through annual reports, enabling comparisons with own prior and other centres´ results.

  • OtherImplementation support

    On-site support to implement guidelines on secondary prevention applying practice facilitation - a multifaceted approach carried out by CR experts who enable personnel at intervention centres to address and overcome challenges in implementing guidelines.

06

What researchers measure

Primary outcomes

  1. Adherence score

    The adherence score reflects center-level adherence to CR processes and structures as recommended in national guidelines on secondary prevention. The score is derived from 39 variables capturing guideline-directed CR structure and processes collected on center-level through the national cardiac registry SWEDEHEART. The score ranges from 0 (worst) to 39 (best).

    Time frame: 3 years

Secondary outcomes

  1. Blood pressure target attainment

    For patients \<70 years of age \<130/80 mmHg and for patients ≥70 years \<140/80 mmHg (yes/no)

    Time frame: One year

  2. Systolic blood pressure

    Continuous variable in mmHg

    Time frame: One year

  3. Low-density lipoprotein cholesterol target attainment

    \<1.4 mmol/L (yes/no)

    Time frame: One year

  4. Low-density lipoprotein cholesterol

    Continuous variable in mmol/L

    Time frame: One year

  5. Self-reported quality of life

    Measured using EuroQoL-Visual Analogue Scale (EQ-VAS) - a vertical visual analogue scale with a range of values between 100 (best imaginable health) and 0 (worst imaginable health)

    Time frame: One year

  6. Self-reported smoking status

    Never smoker, former smoker (\>1 month) or current smoker

    Time frame: One year

  7. Self-reported dietary habits

    Dietary habits are assessed by self-report through four questions covering intake of fruit, vegetables, fish and sweets. Each question gives points ranging from 0 (worst) to 3 (best), summing up to a total score of 0-12 points.

    Time frame: One year

  8. Self-reported physical activity

    Number of days during the last week the patient has been physically active for a minimum of 30 minutes (at least 10 minutes at a time) with activity causing shortness of breath and a slightly increased pulse, corresponding to a brisk walk. Permissible values can thus range from 0 days (worst) to 7 days (best).

    Time frame: One year

  9. Attendance in an exercise-based CR programme

    Attended for at least 3 months (yes/no)

    Time frame: One year

  10. Major adverse cardiovascular events (MACE)

    A composite endpoint of the following events: * cardiovascular mortality * non-fatal MI * non-fatal ischemic stroke * coronary revascularization * hospitalization for new or worsening heart failure

    Time frame: Five years

  11. Total mortality

    Death from any cause.

    Time frame: Five years

  12. Acceptability of the implementation support

    Acceptability reflects the degree to which the intervention is perceived as being feasible, desirable, and appropriate by stakeholders (healthcare providers, i.e., the CR team and organizational leaders) and the level of preparedness of the organization to adopt the intervention. Acceptability will be assessed through semi-structured interviews with healthcare personnel at centers subject to the implementation intervention. Interview guides, allowing for flexibility in terms of order and form of questions and topics, using mainly open-ended and neutral questions will be developed. The exact number of interviews will be decided on after start of the study and will continue until a) no new concepts or categories are identified and b) when there is no need for further elaboration of these.

    Time frame: Assessed at the time of implementation

  13. Adoption of the implementation support

    Adoption determines the extent to which the intervention is used in practice. Adoption of the implementation support will be assessed through semi-structured interviews with healthcare personnel at centers subject to the implementation intervention.

    Time frame: Assessed six months after the implementation support has been provided

  14. Fidelity of the implementation support

    Fidelity reflects the degree to which the implementation used in practice adheres to the original design of the intervention. Fidelity will be assessed through semi-structured interviews with healthcare personnel at centers subject to the implementation intervention.

    Time frame: Assessed six months after the implementation support has been provided

  15. Implementation cost and cost effectiveness

    Reflects resources required to implement the intervention, including the cost of material, staff, and any other expenses incurred as a result of the implementation of the intervention. Based on the cost estimates and the effect of the implementation assistance on patient outcomes, the economic evaluation will then be able to calculate cost-effectiveness ratios.

    Time frame: Assessed at the time of implementation

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — The data to be used in this study is based on the SWEDEHEART registry. Access to data from the registry needs to be applied for and third-party data usage is not allowed, irrespective of whether the data contain potentially identifying or sensitive data or not. Instead, given ethical study approval from the Swedish Ethical Review Authority, access to SWEDEHEART data can be applied for from the Uppsala Clinical Research Center (UCR) in Sweden. Further information can be found on the UCR www.ucr.uu.se/en/ and Swedish Ethical Review Authority etikprovningsmyndigheten.se/ websites.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2026, 38 months after the start.

Of 322 non-industry interventional studies with no phase under Myocardial Infarction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's planned 38 months is close to that.

Counting every sponsor, half of 355 studies reached it within 34 months; a quarter within 15 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2023
First posted
Jun 5, 2023
StartActual
Oct 1, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2030
Last update
Nov 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05889416
Lead sponsor
Skane University Hospital
Responsible party
Margret Leosdottir (Senior Cardiology Consultant, Associate Professor, Skane University Hospital) — Principal investigator
First posted
Jun 5, 2023
Start date
Oct 1, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2030 (estimated)
Last update
Nov 29, 2024

Study contacts

Margret Leosdottir
principal investigator · Skane University Hospital Malmö

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion